Structure-based virtual screening and docking studies for the identification of novel inhibitors against wild and drug resistance strains of HIV-1 RT
- 353 Downloads
Non-nucleoside reverse transcriptase inhibitors (NNRTIs) are structurally diverse group of compounds which binds to reverse transcriptase (RT) enzyme of Human Immunodeficiency Virus (HIV). Like other anti-HIV drugs, long-term clinical effectiveness of approved NNRTIs has been hampered due to the rapid development of drug resistance. Therefore, attempts have been made to discover the NNRTIs active against both drug sensitive, as well as drug resistant strains of HIV-1 RT. In the present study, using structure-based virtual screening online database of small molecules was screened against wild strain of HIV-1 RT. Among the screened ligands, top thirty hits which exhibited lowest G score against wild HIV RT were further evaluated against two clinically drug resistance strains of HIV-1 RT. Docking study of these top thirty hits revealed that around nine ligands exhibited significant binding affinity (G score less than −10) against wild, as well as two drug resistance strains of HIV-1 RT. These nine compounds were further selected for in silico prediction of physiochemical, absorption, distribution, metabolism, excretion, and toxicity (ADMET) parameters using QikProp module of Schrödinger and online tool admetSAR.
KeywordsVirtual screening Docking Maybridge HIV Reverse transcriptase Mutation
Authors gratefully acknowledge BITS-Pilani for providing the necessary facilities to do this work. This work was carried out under a Grant from Science and Engineering Research Board of Department of Science and Technology, New Delhi (Ref. No: SR/FT/LS-58/2011).
Conflict of interest
The authors declared that there is no conflict of interest.
- Bell FW, Cantrell AS, Hoegberg M, Jaskunas SR, Johansson NG, Jordan CL, Kinnick MD, Lind P, Morin JM (1995) Phenethylthiazolethiourea (PETT) compounds, a new class of HIV-1 reverse transcriptase inhibitors. Synthesis and basic structure activity relationship studies of PETT analogs. J Med Chem 38:4929–4936CrossRefPubMedGoogle Scholar
- Hopkins AL, Ren J, Esnouf RM, Willcox BE, Jones EY, Ross C, Miyasaka T, Walker RT, Tanaka H, Stammers DK, Stuart DI (1996) Complexes of HIV-1 reverse transcriptase with inhibitors of the HEPT series reveal conformational changes relevant to the design of potent non-nucleoside inhibitors. J Med Chem 39:1589–1600CrossRefPubMedGoogle Scholar
- La Regina G, Coluccia A, Brancale A, Piscitelli F, Famiglini V, Cosconati S, Maga G, Samuele A, Gonzalez E, Clotet B, Schols D, Este JA, Novellino E, Silvestri R (2012) New nitrogen containing substituents at the indole-2-carboxamide yield high potent and broad spectrum indolylarylsulfone HIV-1 non-nucleoside reverse transcriptase inhibitors. J Med Chem 55:6634–6638CrossRefPubMedGoogle Scholar
- Nichols SE, Domaoal RA, Thakur VV, Tirado-Rives J, Anderson KS, Jorgensen WL (2009) Discovery of wild-type and Y181C mutant non-nucleoside HIV-1 reverse transcriptase inhibitors using virtual screening with multiple protein structures. J Chem Inf Model 49:1272–1279CrossRefPubMedCentralPubMedGoogle Scholar
- Paul AJ, Janssen PJ, Lewi PJ, Arnold E, Daeyaert F, Jonge M, Heeres J, Koymans L, Stoffels P (2005) In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile (R278474, rilpivirine). J Med Chem 48:1901–1909CrossRefGoogle Scholar
- Ren J, Nichols CE, Chamberlain PP (2007) Relationship of potency and resilience to drug resistance mutations for GW420867X revealed by crystal structures of inhibitor complexes for wild-type, Leu100Ile, Lys101Glu and Tyr188Cys mutant HIV-1 reverse transcriptases. J Med Chem 50:2301–2309CrossRefPubMedGoogle Scholar
- Romines KR, Freeman GA, Schaller LT, Cowan JR, Gonzales SS, Tidwell JH, Andrews CW 3rd, Stammers DK, Hazen RJ, Ferris RG, Short SA, Chan JH, Boone LR (2006) Structure-activity relationship studies of novel benzophenones leading to the discovery of a potent, next generation HIV nonnucleoside reverse transcriptase inhibitor. J Med Chem 49:727–739CrossRefPubMedGoogle Scholar